Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.

Gold DT, Beckett T, Deal C, James AL, Mohseni M, McMillan A, Bailey T, Pearman L, Caminis J, Wang Y, Williams SA, Kernaghan JM

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA24 Apr 2024Cited by 2 (Europe PMC)

PMID38653862PMCIDPMC11282169DOI10.1007/s00198-024-07070-zPepBankPUB-38653862

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyOther
After abaloparatide completion, 82/162 women transitioned to another osteoporosis medication.
In plain wordsAfter abaloparatide, 50.6% of assessed women transitioned to another osteoporosis medication.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTransition to another medication
Study
n = 162
Outcome group
Patterns of use · Musculoskeletal
Studied dose
Dose not stated
Measurements
Transition to another osteoporosis medication
50.6%
after completing abaloparatide course
Source sentences
Summary
Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
Report a problemFND-3865386207
02HumanObservational studySafety outcome
Tolerability accounted for 22.8% of reported abaloparatide discontinuation reasons.
In plain wordsTolerability accounted for 22.8% of reported reasons for stopping abaloparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTolerability discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Measurements
Tolerability as reason for discontinuation
22.8%
reasons for treatment discontinuation
Source sentences
Summary
The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%).
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
Report a problemFND-3865386206
03HumanObservational studyOther
The median interval from abaloparatide completion to subsequent medication was 21 days.
In plain wordsThe median interval between abaloparatide completion and the next medication was 21 days.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableInterval to subsequent medication
Study
n: not reported in source
Outcome group
Patterns of use · Musculoskeletal
Studied dose
Dose not stated
Measurements
Median time to follow-on medication
21 days
after abaloparatide course completion
Source sentences
Summary
The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
Report a problemFND-3865386208

Studies that did not test the peptide alone7

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

04HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women receiving abaloparatide, 96.0% had at least one osteoporosis management visit during follow-up.
In plain wordsAmong women receiving abaloparatide, 96.0% had an osteoporosis management visit.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableOsteoporosis management visits
Study
n = 173
Outcome group
Patterns of use · Musculoskeletal
Measurements
Patients with at least one osteoporosis management visit
96%
during follow-up
Source sentences
Summary
During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386201
05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women receiving abaloparatide, 55.5% had access to a medication support program.
In plain wordsAmong women receiving abaloparatide, 55.5% had access to medication support.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableMedication support access
Study
n = 173
Outcome group
Patterns of use · Musculoskeletal
Measurements
Patients with access to medication support program
55.5%
during follow-up
Source sentences
Summary
During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386202
06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
At abaloparatide initiation, 78.6% of patients had received other osteoporosis medications.
In plain wordsBefore abaloparatide, 78.6% of patients received other osteoporosis medications.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicablePrior osteoporosis medication use
Study
n = 173
Outcome group
Patterns of use · Musculoskeletal
Measurements
Prior osteoporosis medication use
78.6%
at abaloparatide initiation
Source sentences
Summary
At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386209
07HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among women assessed for completion, 105/162 completed abaloparatide as prescribed.
In plain wordsAmong women assessed, 64.8% completed abaloparatide as prescribed.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTreatment completion
Study
n = 162
Outcome group
Patterns of use · Musculoskeletal
Measurements
Completed treatment as prescribed
64.8%
105/162 patients
Source sentences
Summary
The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386204
08HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Women receiving abaloparatide had a median therapy duration of 18.6 months.
In plain wordsWomen received abaloparatide for a median of 18.6 months.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTherapy duration
Study
n: not reported in source
Outcome group
Patterns of use · Musculoskeletal
Measurements
Median duration of therapy
18.6 months
abaloparatide treatment
Source sentences
Summary
The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386203
09HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Financial reasons accounted for 31.2% of reported abaloparatide discontinuation reasons.
In plain wordsFinancial reasons accounted for 31.2% of reported reasons for stopping abaloparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableFinancial discontinuation
Study
n: not reported in source
Outcome group
Patterns of use · Musculoskeletal
Measurements
Discontinuation for financial reasons
31.2%
reasons for treatment discontinuation
Source sentences
Summary
The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%).
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386205
10HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
The mean interval from prior osteoporosis medication discontinuation to abaloparatide initiation was 1.7 years (SD 3.2).
In plain wordsThe mean interval between previous osteoporosis treatment and abaloparatide initiation was 1.7 years.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableInterval before abaloparatide initiation
Study
n: not reported in source
Outcome group
Patterns of use · Musculoskeletal
Measurements
Mean time since prior medication discontinuation
1.7 years
before abaloparatide initiation
SD of time since prior medication discontinuation
3.2 years
before abaloparatide initiation
Source sentences
Summary
Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years.
1 context sentence(design, population, supporting numbers)
Summary · context
Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3865386210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.